Bcal Diagnostics Ltd Total Liabilities

Latest as of June 2026: AU$8.49 Million AUD ≈ $6.01 Million USD

Bcal Diagnostics Ltd total liabilities. Based on the latest financial reports, Bcal Diagnostics Ltd (BDX) has total liabilities worth AU$8.49 Million AUD (≈ $6.01 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Bcal Diagnostics Ltd (BDX) liquid assets ratio to evaluate the company's liquid asset resilience ratio.

Total Liabilities of Bcal Diagnostics Ltd (2017–2025)

Total liabilities of Bcal Diagnostics Ltd from 2017 to 2025. This chart illustrates how Bcal Diagnostics Ltd's total liabilities have evolved over time, based on quarterly financial data.

Bcal Diagnostics Ltd Competitors by Total Liabilities

The table below lists competitors of Bcal Diagnostics Ltd ranked by their total liabilities.

Company Country Total Liabilities
Consus Enerji Isletmeciligi ve Hizmetleri AS
IS:CONSE
Turkey TL5.87 Billion
Dongbang Ship Machinery Co. Ltd
KQ:099410
Korea ₩17.09 Billion
Alpha Group International plc
LSE:ALPH
UK GBX294.65 Million
Dadi Early-Childhood Education Group Ltd
TWO:8437
Taiwan NT$441.35 Million
INTERSHOP Communications Aktiengesellschaft
XETRA:ISHA
Germany €22.65 Million
Crypto Blockchain Industries SA
PA:ALCBI
France €14.13 Million
SD SYSTEM Co. Ltd
KQ:121890
Korea ₩1.85 Billion
M VEST WATER NK-00227652
F:7YA
Germany €13.43 Million

Liability Composition Analysis (2017–2025)

This chart breaks down Bcal Diagnostics Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Bcal Diagnostics Ltd (BDX) total assets.

Liquidity & Leverage Metrics

Bcal Diagnostics Ltd Total Liabilities Ratios Explained

Bcal Diagnostics Ltd total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.

Metric Value Description
Current Ratio 1.36 Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio N/A More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio N/A Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity -10.27 Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets 1.11 Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Bcal Diagnostics Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Bcal Diagnostics Ltd (2017–2025)

The table below shows the annual total liabilities of Bcal Diagnostics Ltd from 2017 to 2025.

Year Total Liabilities Change
2025-12-31 AU$8.49 Million
≈ $6.01 Million
+130.14%
2024-12-31 AU$3.69 Million
≈ $2.61 Million
+0.29%
2023-12-31 AU$3.68 Million
≈ $2.60 Million
+16.46%
2022-12-31 AU$3.16 Million
≈ $2.23 Million
+232.21%
2021-12-31 AU$950.42K
≈ $672.48K
+80.82%
2020-12-31 AU$525.60K
≈ $371.90K
+38.09%
2019-12-31 AU$380.64K
≈ $269.33K
+629.99%
2018-12-31 AU$52.14K
≈ $36.89K
-91.88%
2017-12-31 AU$641.86K
≈ $454.16K
--

About Bcal Diagnostics Ltd

AU:BDX Australia Diagnostics & Research
Market Cap
$21.91 Million
AU$30.97 Million AUD
Market Cap Rank
#24681 Global
#1001 in Australia
Share Price
AU$0.08
Change (1 day)
+5.00%
52-Week Range
AU$0.05 - AU$0.14
All Time High
AU$0.25
About

BCAL Diagnostics Limited, a biotechnology company, engages in developing a novel blood screening test to support the early diagnosis and monitoring of breast cancer in Australia. It is involved in the development and commercialization of BREASTESTplus; Avantect Pancreatic; Avantect Ovarian; BREASTESTplus 2; BREASTEST Monitor; and Avantect multi-cancer test. The company was incorporated in 2010 an… Read more